<DOC>
	<DOCNO>NCT02312661</DOCNO>
	<brief_summary>Molecularly target agent inhibit mammalian target rapamycin ( mTOR ) pathway and/or circumvent p53 induction apoptosis excite potential target ovarian cancer . Metformin biguanide , widely use treatment type 2 diabetes mellitus , show anti-cancer activity preclinical study . The main mechanism metformin 's effect mTOR pathway inhibition , addition , show circumvent p53-induced apoptosis make exciting , potentially effective drug ovarian cancer .</brief_summary>
	<brief_title>Study Metformin With Carboplatin/Paclitaxel Chemotherapy Patients With Advanced Ovarian Cancer</brief_title>
	<detailed_description>A phase Ib , single-centre , dose-escalation trial traditional escalation rule fix dose level ( `` 3 + 3 '' rule ) . The recommended phase II dose define maximum predefined dose level 0 3 ≤ 1 6 subject experience drug-related dose limit toxicity ( DLT ) cycle 1 2 treatment . An estimated 10-20 patient require study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients advanced stage ( FIGO IIIIV ) , histologically confirm document epithelial ovarian carcinoma Patients eligible neoadjuvant carboplatin/paclitaxel chemotherapy prior surgical debulking OR patient relapse progressive ovarian cancer initial treatment eligible palliative carboplatin/paclitaxel chemotherapy Eastern Cooperative Oncology Groupperformance status ( ECOGPS ) 02 Age ≥ 18 year Laboratory Requirements within 7 day prior enrolment : absolute neutrophil count ( ANC ) ≥1.5 x 109/L platelet &gt; 100 x 109/L hemoglobin &gt; 9g/dl . Patients may transfuse use erythropoietin maintain hemoglobin value ≥ 9 g/dl . hepatic function : bilirubin ≤1.5×upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) /ALT≤2.5×ULN estimate creatinine clearance ≥ 60ml/min Before patient registration/randomization , write informed consent trial must give accord International Conference Harmonisation ( ICH ) / good clinical practice ( GCP ) , national/local regulation . Current recent ( within 30 day first study dose ) treatment another investigational drug participation another investigational study . Metformin within 4 week prior enrolment . Symptomatic central nervous system ( CNS ) metastasis Preexisting peripheral neuropathy ≥ Common toxicity criterion ( CTC ) grade 2 . Pregnant lactating female . Serum pregnancy test assess within 7 day prior study treatment start , within 14 day confirmatory urine pregnancy test within 7 day prior study treatment start . Women childbearing potential ( define &lt; 2 year last menstruation surgically sterile ) use effective , nonhormonal mean contraception ( intrauterine contraceptive device , barrier method contraception conjunction spermicidal jelly ) study 6 month last study medication . Known hypersensitivity study drug excipients . Serious active infection require i.v . antibiotic enrolment . Unstable medical condition . Evidence medical condition , physical examination laboratory finding may interfere plan treatment , affect patient compliance place patient high risk treatment related complication .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>metformin</keyword>
	<keyword>carboplatin</keyword>
	<keyword>paclitaxel</keyword>
</DOC>